Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
129 hedge funds and large institutions have $363M invested in Keryx Biopharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 36 reducing their positions, and 27 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
2% less funds holding
Funds holding: 132 → 129 (-3)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
34% less call options, than puts
Call options by funds: $3.96M | Put options by funds: $5.98M
36% less capital invested
Capital invested by funds: $563M → $363M (-$201M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$22M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 3 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$5.99M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$37.1M |
| 2 |
Millennium Management
New York
|
-$10.3M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$5.36M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$5.33M |
| 5 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
-$4.87M |
KERX Hedge Fund Activity: Q4 2017 in Review
129 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2017, worth a combined $363M — down 36% from $563M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of KERX and 24 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 42 added.
The largest buyer was Abrams Capital Management, adding an estimated $22M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $37.1M sold.
- 129 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2017, down from 132 in Q3 2017.
- Funds reported $363M of Keryx Biopharmaceuticals Inc stock for Q4 2017, down 36% quarter-over-quarter.
- 24 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2017 and 27 closed out, a net change of -3 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q4 2017 was Abrams Capital Management, an estimated $22M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q4 2017 was Consonance Capital Management, an estimated $37.1M sold.
Based on aggregated 13F filings for Q4 2017.